The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Current Status of GLP-1 Medications The FDA has officially determined that the shortage of both semaglutide and tirzepatide injection products is now resolved. Semaglutide: The FDA determined on ...

Stephanie Anderson Witmer is a freelance journalist based in Pennsylvania. Her work has been published in other top magazines and digital publications, including Prevention, Good Housekeeping ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online in JAMA Psychiatry. Christian S.

Two recent tools in the battle for weight loss have been showing incredible results: Semaglutide and Tirzepatide. Stephanie Davison from Skin Envy Non-Surgical Weight Loss Center, and Registered ...

We all know that Ozempic, a GLP-1 receptor agonist medication, also called semaglutide, causes weight loss. On average, high-dose semaglutides, like in Wegovy, cause people to lose somewhere ...

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

The study could help inform conversations between providers and patients who are considering whether to try weight-loss medications or surgery first. Researchers studied whether taking semaglutide ...

(Image Credits: Pexel) A new study has revealed that off-label use of semaglutide (Ozempic) and tirzepatide (Mounjaro) leads to significant reductions in HbA1c levels and body weight among adults ...

[vi] In light of the OFA’s lawsuit, the FDA issued clarifying guidance on when compounders must cease compounding semaglutide. For compounders that have relied on the drug shortage to compound ...